vedrop
recordati rare diseases - tocofersolan - cholestasis; vitamin e deficiency - vitamins - vedrop is indicated in vitamin-e deficiency due to digestive malabsorption in paediatric patients suffering from congenital chronic cholestasis or hereditary chronic cholestasis, from birth (in term newborns) to 16 or 18 years of age, depending on the region.
vedrop 50mgml oral solution
orphan europe (uk - tocofersolan - oral solution - 50mg/1ml
maviret glecaprevir 50 mg / pibrentasvir 20 mg granules sachet
abbvie pty ltd - glecaprevir, quantity: 50 mg; pibrentasvir, quantity: 20 mg - granules - excipient ingredients: copovidone; tocofersolan; propylene glycol monocaprylate; colloidal anhydrous silica; croscarmellose sodium; sodium stearylfumarate; purified water; titanium dioxide; lactose monohydrate; hypromellose; iron oxide red; macrogol 3350; iron oxide yellow - maviret is indicated for the treatment of adult and paediatric patients 3 years and older with chronic hepatitis c virus (hcv) genotype (gt) 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis. this includes patients with hcv gt1 infection who were previously treated with either a regimen of an ns5a inhibitor or with an ns3/4a protease inhibitor but not both classes of inhibitors (see 4.2 dose and method of administration and 5.1 pharmacodynamic properties ? clinical trials).
maviret glecaprevir/pibrentasvir 100 mg/40 mg film-coated tablet blister pack
abbvie pty ltd - glecaprevir, quantity: 100 mg; pibrentasvir, quantity: 40 mg - tablet, film coated - excipient ingredients: propylene glycol monocaprylate; tocofersolan; croscarmellose sodium; sodium stearylfumarate; copovidone; colloidal anhydrous silica; titanium dioxide; lactose monohydrate; hypromellose; iron oxide red; macrogol 3350 - maviret is indicated for the treatment of adult and paediatric patients 3 years and older with chronic hepatitis c virus (hcv) genotype (gt) 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis. this includes patients with hcv gt1 infection who were previously treated with either a regimen of an ns5a inhibitor or with an ns3/4a protease inhibitor but not both classes of inhibitors (see 4.2 dose and method of administration and 5.1 pharmacodynamic properties ? clinical trials).
maviret glecaprevir/pibrentasvir 100 mg/40 mg film-coated tablet bottle
abbvie pty ltd - glecaprevir, quantity: 100 mg; pibrentasvir, quantity: 40 mg - tablet, film coated - excipient ingredients: propylene glycol monocaprylate; tocofersolan; croscarmellose sodium; sodium stearylfumarate; copovidone; colloidal anhydrous silica; titanium dioxide; lactose monohydrate; hypromellose; iron oxide red; macrogol 3350 - maviret is indicated for the treatment of adult and paediatric patients 3 years and older with chronic hepatitis c virus (hcv) genotype (gt) 1, 2, 3, 4, 5, or 6 infection with or without compensated cirrhosis. this includes patients with hcv gt1 infection who were previously treated with either a regimen of an ns5a inhibitor or with an ns3/4a protease inhibitor but not both classes of inhibitors (see 4.2 dose and method of administration and 5.1 pharmacodynamic properties ? clinical trials).
maviret
abbvie limited - glecaprevir 100mg; ; pibrentasvir 40mg; - film coated tablet - active: glecaprevir 100mg pibrentasvir 40mg excipient: colloidal silicon dioxide copovidone croscarmellose sodium hypromellose iron oxide red lactose monohydrate macrogol 3350 propylene glycol monocaprylate sodium stearyl fumarate titanium dioxide tocofersolan - maviret is indicated for the treatment of adults and adolescents 12 years and older with chronic hepatitis c virus (hcv)
liposomal phosphatidyl choline
fit-bioceuticals pty ltd - lecithin, quantity: 0.16 ml/ml - oral liquid - excipient ingredients: glycerol; ethanol; purified water; tocofersolan - maintain/support healthy liver function ; aid/assist/helps metabolism of (state vitamin/mineral/nutrient)
viekira pak
abbvie limited - ombitasvir 12.5mg; paritaprevir 75mg; ritonavir 50mg; dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg; - film coated tablet - active: ombitasvir 12.5mg paritaprevir 75mg ritonavir 50mg excipient: colloidal silicon dioxide copovidone opadry pink 85f140088 propylene glycol monolaurate sodium stearyl fumarate sorbitan laurate tocofersolan active: dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg excipient: colloidal silicon dioxide copovidone croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry beige 85f97497 - indicated for the treatment of genotype 1 chronic hepatitis c infection, including patients with compensated cirrhosis, hiv-1 coinfection, and liver transplant recipients. duration of therapy and addition of ribavirin are dependent on patient population.
viekira pak-rbv
abbvie limited - ombitasvir 12.5mg; paritaprevir 75mg; ritonavir 50mg; dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg; ; ribavirin 200mg; - film coated tablet - active: ombitasvir 12.5mg paritaprevir 75mg ritonavir 50mg excipient: colloidal silicon dioxide copovidone opadry pink 85f140088 propylene glycol monolaurate sodium stearyl fumarate sorbitan laurate tocofersolan active: dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg excipient: colloidal silicon dioxide copovidone croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry beige 85f97497 active: ribavirin 200mg excipient: carnauba wax croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry blue 85f90614 povidone - indicated for the treatment of genotype 1 chronic hepatitis c infection, including patients with compensated cirrhosis, hiv-1 coinfection, and liver transplant recipients. duration of therapy and addition of ribavirin are dependent on patient population.
viekira pak-rbv
abbvie limited - ombitasvir 12.5mg; paritaprevir 75mg; ritonavir 50mg; dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg; ; ribavirin 400mg; ; ribavirin 600mg - film coated tablet - active: ombitasvir 12.5mg paritaprevir 75mg ritonavir 50mg excipient: colloidal silicon dioxide copovidone opadry pink 85f140088 propylene glycol monolaurate sodium stearyl fumarate sorbitan laurate tocofersolan active: dasabuvir sodium monohydrate 270.26mg equivalent to dasabuvir 250 mg excipient: colloidal silicon dioxide copovidone croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry beige 85f97497 active: ribavirin 400mg excipient: carnauba wax croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry blue 85f90553 povidone active: ribavirin 600mg excipient: carnauba wax croscarmellose sodium lactose monohydrate magnesium stearate microcrystalline cellulose opadry blue 85f90623 povidone - indicated for the treatment of genotype 1 chronic hepatitis c infection, including patients with compensated cirrhosis, hiv-1 coinfection, and liver transplant recipients. duration of therapy and addition of ribavirin are dependent on patient population.